Physician profile
Boris Ilg
NPI 1982763835
$447.18
in general payments reported to CMS, 2019-2025
9 companies · $46.90 in 2025
The $46.90 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.87 · 2020: $83.41 · 2021: $67.36 · 2022: $19.43 · 2023: $105 · 2024: $100 · 2025: $46.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $252.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $140.90 | 2022-2025 | Rocklatan, Clareon, Rhopressa |
| Allergan, INC. | $84.95 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $65.99 | 2023-2024 | Xiidra, Infuse, Vyzulta |
| Sun Pharmaceutical Industries INC. | $47.45 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $24.08 | 2020 | |
| Harrow Eye, LLC | $23.15 | 2024 | Vevye |
| Thea Pharma INC. | $21.04 | 2023 | |
| Oyster Point Pharma, INC. | $20.46 | 2023 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Ilg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.